Evidence map›Paper›PMID 42352329›Full record

ArticleBiomolecules2026

The Efficacy of Antihypertensive Drugs and miR-632 Inhibition on Parietal Remodeling in a Model of Marfan Thoracic Aortic Aneurysm.

Sonia Terriaca, Maria Giovanna Scioli, Fabio Bertoldo, Paolo Nardi, Gian Paolo Novelli, Beatrice Belmonte, Tommaso D'Anna, Carmela Rita Balistreri, Calogera Pisano, Amedeo Ferlosio and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sonia TerriacaAnatomic Pathology, Azienda Ospedaliera Universitaria Policlinico Tor Vergata, 00133 Rome, Italy.
Maria Giovanna ScioliAnatomic Pathology, Department of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-8458-4108
Fabio BertoldoCardiac Surgery Unit, Azienda Ospedaliera Universitaria Policlinico Tor Vergata, 00133 Rome, Italy.
Paolo NardiCardiac Surgery Unit, Department of Surgery, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-4005-3110
Gian Paolo NovelliDivision of Cardiology, Azienda Ospedaliera Universitaria Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-6010-3234
Beatrice BelmonteTumor Immunology Unit, Department of Health Sciences, University of Palermo, 90134 Palermo, Italy.ORCID 0000-0001-9668-0925
Tommaso D'AnnaAnatomic Pathology, Department of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy.
Carmela Rita BalistreriCellular and Molecular Laboratory, Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of Palermo, 90134 Palermo, Italy.ORCID 0000-0002-5393-1007
Calogera PisanoCardiac Surgery Unit, Department of Precision Medicine in Medical Surgical and Critical Area (Me.Pre.C.C.), University of Palermo, 90134 Palermo, Italy.
Amedeo FerlosioAnatomic Pathology, Department of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy.
Augusto D'OnofrioCardiac Surgery Unit, Department of Surgery, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-9835-9091
Augusto OrlandiAnatomic Pathology, Department of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0001-7202-5854

Funding

European Union European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and Strengthening of Biomedical Research in the NHS (PNRR-MR1-2022-12376699)
6 · The paper itself

Abstract

backgroundMarfan syndrome (MFS) is a connective tissue disorder caused by METHODS AND

resultsUsing an ex vivo paired experimental framework based on independent biological pools of human TAA tissue, gene expression and Western blot analyses demonstrated that only losartan significantly reduced miR-632 and vascular degeneration markers. Notably, combined treatment with ramipril and carvedilol compromised losartan's efficacy, highlighting the need for careful therapeutic selection. In this ex vivo setting, miR-632 inhibition demonstrated a promising capacity to counteract aortic remodeling, serving as a mechanistic proof-of-concept that warrants further preclinical in vivo validation.

conclusionsOur data emphasize that choosing the right treatment in MFS aortopathy requires understanding its specific impact on cellular pathways. Our findings identify losartan as the most effective standard drug in this model, while suggesting miR-632 as a potential future target to stabilize the aortic wall and, prospectively, delay surgery.

Indexed as

Antihypertensive AgentsAortic Aneurysm, ThoracicMarfan SyndromeMicroRNAsVascular RemodelingAnimalsCarvedilolDisease Models, AnimalFibrillin-1HumansLosartanMaleRamiprilAntihypertensive AgentsCarvedilolFibrillin-1LosartanMicroRNAsRamiprilaortic wall remodelingcarvedilollosartanMarfan syndromemiR-632 inhibitionramiprilthoracic aortic aneurysm

Identifiers

PMID42352329
PMCPMC13296651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.